TY - JOUR
T1 - Human herpesvirus 6 viremia in bone marrow transplant recipients
T2 - Clinical features and risk factors
AU - Yoshikawa, Tetsushi
AU - Asano, Yoshizo
AU - Ihira, Masaru
AU - Suzuki, Kyoko
AU - Ohashi, Masahiro
AU - Suga, Sadao
AU - Kudo, Kazuko
AU - Horibe, Keizo
AU - Kojima, Seiji
AU - Kato, Koji
AU - Matsuyama, Takaharu
AU - Nishiyama, Yukihiro
N1 - Funding Information:
Financial support: Fujita Health University; Japan Society for the Promotion of Science (JSPS-RFTF97L00703); Ministry of Education, Science, and Culture, Japan (grant-in-aid for scientific research).
PY - 2002/4/1
Y1 - 2002/4/1
N2 - Human herpesvirus 6 (HHV-6) infection was studied in 82 bone marrow transplant (BMT) recipients (72 allogeneic, 10 autologous). All recipients and 30 donors were seropositive for HHV-6 antibody at the time of bone marrow transplantation. Thirty-one recipients (37.8%) had HHV-6 viremia 2-4 weeks after transplantation. The incidence of HHV-6 viremia was significantly higher among allogeneic BMT recipients than in autologous BMT recipients (P = .011). Therefore, the following analyses of allogeneic BMT recipients were carried out (n = 72). Geometric mean antibody titers (log10) were significantly higher in recipients without viremia than in those with viremia (1.84 ± 0.39 vs. 1.61 ± 0.42; P = .022). Logistic regression analysis demonstrated that leukemia or lymphoma is an independent risk factor (P = .031) for HHV-6 viremia. Rash occurring within 1 month after transplantation was observed in 17 (54.8%) of 31 recipients with HHV-6 viremia but in only 8 (19.5%) of 41 recipients without HHV-6 viremia (P = .001).
AB - Human herpesvirus 6 (HHV-6) infection was studied in 82 bone marrow transplant (BMT) recipients (72 allogeneic, 10 autologous). All recipients and 30 donors were seropositive for HHV-6 antibody at the time of bone marrow transplantation. Thirty-one recipients (37.8%) had HHV-6 viremia 2-4 weeks after transplantation. The incidence of HHV-6 viremia was significantly higher among allogeneic BMT recipients than in autologous BMT recipients (P = .011). Therefore, the following analyses of allogeneic BMT recipients were carried out (n = 72). Geometric mean antibody titers (log10) were significantly higher in recipients without viremia than in those with viremia (1.84 ± 0.39 vs. 1.61 ± 0.42; P = .022). Logistic regression analysis demonstrated that leukemia or lymphoma is an independent risk factor (P = .031) for HHV-6 viremia. Rash occurring within 1 month after transplantation was observed in 17 (54.8%) of 31 recipients with HHV-6 viremia but in only 8 (19.5%) of 41 recipients without HHV-6 viremia (P = .001).
UR - http://www.scopus.com/inward/record.url?scp=0036535133&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036535133&partnerID=8YFLogxK
U2 - 10.1086/339411
DO - 10.1086/339411
M3 - Article
C2 - 11920307
AN - SCOPUS:0036535133
SN - 0022-1899
VL - 185
SP - 847
EP - 853
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 7
ER -
